Allorion Therapeutics named ARTS-011 as the development candidate for its TYK2 program. The preclinical data for ARTS-011 will be presented on May 7 in a poster session at the American Association of Immunologists (AAI) Annual Meeting 2022 in Portland, Oregon.
Read More